NATCO Pharma completes Adcock Ingram delisting, expands African presence with US$226mn acquisition
NATCO Pharma completed the acquisition and delisting of South African firm Adcock Ingram for US$ 226 million (₹1880.89 crore), securing a 35.75% stake and expanding its global footprint in Africa.
The acquisition of a 35.75% stake in a major South African pharmaceutical company for US$ 226 million (₹1880.89 crore) represents a substantial strategic expansion for NATCO Pharma, significantly impacting its global market position and future revenue potential.
The successful completion of a strategic acquisition of a significant stake in a well-established company like Adcock Ingram is a positive development, expanding NATCO Pharma's market presence and growth opportunities.
* NATCO Pharma Limited announced the successful completion of the delisting of Adcock Ingram Holdings Limited from the Johannesburg Stock Exchange (JSE) as of November 11, 2025. * This marks the culmination of a strategic acquisition where NATCO Pharma acquired a 35.75% stake in Adcock Ingram. * The transaction was valued at approximately US$ 226 million (₹1880.89 crore) and ZAR 4 billion (₹1792 crore). * Adcock Ingram, established in 1891, is a prominent South African pharmaceutical company known for trusted brands such as Panado, Myprodol, Epi-Max, Citro-soda, and Allergex. * NATCO Pharma's offer of ZAR 75 (US$ 4.36) per share to acquire minority shareholders' stakes was made in July 2025 and received approval in October 2025. * This acquisition establishes NATCO Pharma's market presence in South Africa and is expected to create new opportunities for growth and innovation in the region. * Rajeev Nannapaneni, CEO, NATCO Pharma, stated, “This acquisition represents a significant step in our strategic growth plan across the globe. We are committed to preserving the rich legacy of Adcock Ingram while enhancing its capabilities to better serve the healthcare needs of communities across Africa and beyond.”
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.